Interní Med. 2010; 12(2): 104-108

Carcinoid - Neuroendocrine tumor with many symptoms, less frequent cause of diarhoe

MUDr.Dagmar Jackuliaková1, doc.MUDr.Zdeněk Fryšák, CSc.1, MUDr.Ladislav Faltýnek, CSc.1, MUDr.Tomáš Tichý2, prof.MUDr.Vlastimil Ščudla, CSc.1
1 III. interní klinika FN Olomouc
2 Ústav patologie FN Olomouc

Carcinoid is a tumor originated in cells of neuroendocrine system and representing more than 50 % of neuroendocrine tumors. There are

different carcinoid forms – tumors of undetermined significance, but also metastatic tumors with different degree of dedifferentiation.

The tumor affects gastrointestinal system including pancreas, pulmonary system, ovary and thyroid gland. It is often asymptomatic for

long time or it can produce symptoms given by its localisation. The typical carcinoid syndrome caused by serotonine hypersecretion is

found just in 10 % of patients (up to 40 % patients with intestinal carcinoid). Typical symptoms are flush, diarrhoea, dyspnoe attacks, and

carcinoid heart disease in about 30 % of cases, too. Desmoplastic effect of serotonine is responsible for development of retroperitoneal

fibrosis, but also local peritoneal adhesions, which can caused ileus or hydronephrosis. The diagnosis is based on serum chromogranin

A measurement, 5-hydroxyindolacetic acid 24 hour output in urine and characteristic histology and immunohistologic examination.

Radical surgery is curative for localised carcinoids. There is a possibility to use tumor mass debulking surgery in metastatic form of disease.

Somatostatine analogues, interferon alfa, chemotherapy, and radionuclids linked to peptide-receptors are contemporary ways

of treatment.

Keywords: carcinoid, carcinoid syndrome

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jackuliaková D, Fryšák Z, Faltýnek L, Tichý T, Ščudla V. Carcinoid - Neuroendocrine tumor with many symptoms, less frequent cause of diarhoe. Interní Med. 2010;12(2):104-108.
Download citation

References

  1. Lukáš M, Louthan O. Neuroendokrinní nádory trávicího traktu. Maxdorf, Praha 2006.
  2. Petružalka L. (ed.) Karcinoid. Maxdorf, Praha 2004.
  3. Solcia E, Klöppel G, Sobin LH, et al. Histological typing of endocrine tumours (WHO International Histological Classification of Tumours). 2nd edition. Springer Verlag, New York, USA, 2000. Go to original source...
  4. Zamrazil V. Neuroendokrinní (difuzní endokrinní) systém a nádory, které z něho vycházejí. In Stárka L, et al. Pokroky v endokrinologii. Maxdorf, Praha 2007.
  5. Šachlová M, Vorlíček J. O neuroendokrinních nádorech. Karcinoid. http://www.linkos.cz/pacienti/karcinoid_clanek.php
  6. Greenspan FS, Baxter JD. Základní a klinická endokrinologie. H&H 2003.
  7. Eriksson B, et al. Consensus ENETS Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors - Well-Differentiated Jejunal-Ileal Tumor/Carcinoma. Neuroendocrinology 2008: 87: 8-19. Go to original source... Go to PubMed...
  8. Louthan O. Neuroendokrinní tumory appendixu. Vnitř Lék 2009; 55 (11): 1051-1055. Go to PubMed...
  9. Cempírková V, Havránek P. Karcinoid. Vnitř Lék 2005, 51: 1011-1028.
  10. Louthan O. Neuroendokrinní tumory tenkého střeva - jejuna a ilea. Čes a Slov Gastroent a Hepatol 2009; 63(6): 284-291.
  11. Slováček L, Blažek M, Bartoň P, et al. Karcinoid appendixu. Medicína po promoci 2004; 7: 370-372.
  12. Vítek P. Přehled možností terapeutického ovlivnění karcinoidního syndromu. Remedia 1999; 3: 164-171.
  13. Klener P, et al. Klinická onkologie. Praha: Galén 2002.
  14. Falconi M, et al. ENETS Guidelines: Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma. Neuroendocrinology 2006: 86: 196-211. Go to original source... Go to PubMed...
  15. Oberg K, et al. Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4). Go to original source... Go to PubMed...
  16. Šachlová M, Vyzula R, Novák J. Karcinoid. Klinická onkologie 2003; 3: 130-133.
  17. Reprint doporučených postupů pro léčbu neuroendokrinních nádorů z 9. vydání. Kooperativní skupina pro neuroendokrinní nádory, ČOS. www.neuroendokrinni-nadory.cz
  18. Steinmüller T, et al. Consensus ENETS Guidelines for the Management of Patients with Liver Metastasis from Digestive Neuroendocrine Tumors: Foregut, Midgut, Hingut, and Unknown Primary. Neuroendocrinology 2008: 87: 47-62. Go to original source... Go to PubMed...
  19. Rinke A, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27 (28): 4656-4663. Go to original source... Go to PubMed...
  20. Wanberg E, Nilsson O, Theodersson E, Dahlstrom A, et al. The effect of somatostatin analoque on the release of hormones from human midgut carcinoid tumors cells. Br J Cancer 1991; 64: 23. Go to original source... Go to PubMed...
  21. Bajetta E, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998; 83(2): 372-378. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.